Market revenue in 2023 | USD 1,633.9 million |
Market revenue in 2030 | USD 4,499.3 million |
Growth rate | 15.6% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase III |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 50.35% in 2023. Horizon Databook has segmented the Asia Pacific cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is the fastest-growing market as many developed economies are outsourcing clinical trials to Asia Pacific countries, such as China, India, and South Korea. In addition, the recruitment for clinical trials is increasing in Asia Pacific as compared to North America and Europe, due to the large & diverse patient pools available in these countries.
As per the Novotech’s CEO, Asia pacific is now recognized by clinical phase biotechnology firms for accelerated patient enrollment especially in infectious diseases, oncology, metabolic conditions, immuneoncology, and rare diseases as well as low cost of clinical research combined with experienced investigators & research teams.
The clinical research activity has increased by 10% each year over the past few years. Clinical research in the region is well established with many international pharmaceutical companies & CROs having been in the region for more than 2 decades. There are also key opinion leaders, and centers of excellence across various therapeutic areas in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cell and gene therapy clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account